Medicine
Ventricular Assist Device Complications and Long-Term Management
Quick fact
More than half of VAD patients experience a major complication within two years of implantation, most commonly bleeding or infection.
Why this is interesting
A patient with a ventricular assist device carries a tiny pump inside their chest, yet every month they face a deadly trade-off: too much blood thinner risks a brain bleed, too little risks a stroke. How do doctors walk this line?
Read the full explanation
Understanding Ventricular Assist Device Complications and Long-Term Management
Think of a VAD as an extra engine added to a car whose own engine is failing. It takes over the pumping work of the heart, pushing blood out to the body. The pump sits in the chest, powered by a battery pack through a cable (driveline) that exits the skin. Because the pump's internal surfaces and moving parts are foreign, blood hitting them can trigger clot formation—and clots can cause strokes. To prevent that, patients take strong blood thinners. But those same drugs make bleeding more likely, especially in the digestive tract and brain. Additionally, the driveline acts as a direct entry point for bacteria, leading to infections that are hard to treat because the device is embedded. Long-term management, therefore, is a continuous balancing act: keeping blood thin enough to prevent strokes, thick enough to avoid bleeding, and keeping the exit site clean to prevent infection.
A deeper explanation
The core of VAD complications lies in the interaction between blood and the artificial surfaces of the pump. When blood contacts materials like titanium or polyurethane without the protective lining of endothelium, the coagulation cascade is activated. Tiny clots form, which can grow and either block the pump (pump thrombosis) or break loose, travelling to the brain (embolic stroke). To suppress this activation, patients receive anticoagulants (e.g., warfarin) and antiplatelets (e.g., aspirin). However, these drugs also impair normal haemostasis, leading to an increased risk of bleeding (e.g., gastrointestinal bleeding from angiodysplasia, epistaxis). Another key complication is the driveline infection, occurring because the cable breaches the skin barrier, allowing bacteria to migrate along the driveline and colonise the device. Chronic infections can lead to sepsis and require aggressive antibiotic therapy or even surgical device exchange. Finally, the pump's effect on haemodynamics—reducing pressure in the right heart while increasing systemic flow—can precipitate right heart failure, necessitating careful volume management and inotropic support. Long-term management thus requires a multidisciplinary approach: regular monitoring of pump parameters (flow, speed, power), routine blood tests (INR, haemoglobin), attention to driveline care, and education to recognise signs of complications early.